The main predictor of adverse outcomes (thrombosis and restenosis) after implantation of a stent is the degree of expansion according to published studies using coronary intravascular ultrasound (IVUS). It is unknown whether optical coherence tomography (OCT), in this sense, provides similar information as the IVUS. The aim of this study was to compare the degree<a href="https://solaci.org/en/2015/06/24/ilumien-ii-oct-guided-stenting-versus-ivus/" title="Read more" >...</a>

Article Up to 50% of acute myocardial infarctions are associated to mitral regurgitation of some degree and 10% of these cases present, at least, moderate regurgitation. Ischemic mitral regurgitation is associated to an increase of mortality and morbidity. For surgical patients with moderate regurgitation, the benefits mitral valve repair remain unclear.&nbsp; 301 patients were randomized<a href="https://solaci.org/en/2015/06/24/mitral-valve-repair-in-moderate-ischemic-mitral-regurgitation/" title="Read more" >...</a>

Background: Contrast-induced nephropathy has been the subject of many studies not only because of the morbidity associated with prolonged hospital stay, (with dialysis requirement in some cases), but also with an increase in mortality in these patients. The preventive strategy hydration with saline solution 0.9% NaCl is the choice. However, the infusion rate and total<a href="https://solaci.org/en/2015/06/24/poseidon-study-a-prospective-randomized-single-center-study-comparing-a-sliding-scale-hydration-strategy-for-the-prevention-of-contrast-induced-nephropathy/" title="Read more" >...</a>

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We excluded acute coronary syndromes and left coronary trunk injury. The primary endpoint was death, myocardial infarction or stroke and the secondary main was the sum of<a href="https://solaci.org/en/2015/06/24/freedom-trial-cabg-versus-angioplasty-treatment-for-diabetic-patients-with-multivessel-disease/" title="Read more" >...</a>

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in patients without heart failure reduces mortality and cardiovascular morbidity. Methods and results: The study randomized 612 patients to evaluate the safety and efficacy of early treatment with eplerenone in patients with AMI. The primary end point was a<a href="https://solaci.org/en/2015/06/24/possible-benefit-for-patients-with-acute-myocardial-infarction-but-without-ventricular-dysfunction-2/" title="Read more" >...</a>

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in patients without heart failure reduces mortality and cardiovascular morbidity. Methods and results: The study randomized 612 patients to evaluate the safety and efficacy of early treatment with eplerenone in patients with AMI. The primary end point was a<a href="https://solaci.org/en/2015/06/24/possible-benefit-for-patients-with-acute-myocardial-infarction-but-without-ventricular-dysfunction/" title="Read more" >...</a>

An hour before the presentation of the PREVAIL study, the ACC announced the cancellation of the release of the study results. Due to an error in the email system, results of the study were reported a few hours before his presentation. The ACC in an unprecedented decision cancelled the presentation of the study as well<a href="https://solaci.org/en/2015/06/24/prevail-laa-occlusion-versus-anticoagulation-with-warfarin-to-prevent-stroke-in-patients-with-non-valvular-atrial-fibrillation/" title="Read more" >...</a>